BION BB Biotech AG Ord

62.42USD52.60 CHF · SWX-0.38%Mkt Cap: 3.44B USDP/E: 2.69

BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medica…

Institutional holders1 on file

Key Statistics

Company
Market Cap3.44B USD
Enterprise Value-468.44M USD
Revenue (TTM)1.31B USD
Gross Profit1.31B USD
Net Income (TTM)686.03M USD
Revenue/Share23.77 USD
Last Price62.42 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees10
CountryCH
SectorFinancial Services
IndustryCapital Markets
ISINCH0038389992
Valuation
P/E (Trailing)2.69
P/E (Forward)-79.97
PEG—
EV/EBITDA—
EV/Revenue-0.36
P/S2.63
P/B0.89
EPS (TTM)23.22 USD
EPS (Forward)-0.78 USD
52W Range
48.7173% of range67.52
52W High67.52 USD
52W Low48.71 USD
Profitability
Gross Margin100.00%
Oper. Margin96.19%
EBITDA Margin0.00%
Profit Margin98.49%
ROE20.81%
ROA20.75%
ROIC—
ROCE—
Growth
Revenue Growth-60.80%
Earnings Growth-61.20%
Cash Flow & Leverage
Operating CF232.46M USD
CapEx (TTM)—
FCF Margin63.08%
FCF Yield24.02%
Net Debt-3.91B USD
Net Debt/EBITDA—
Net Debt/FCF-4.73
Balance Sheet
Debt/Equity—
Current Ratio86.52
Quick Ratio86.51
Book Value/Sh70.13 USD
Cash/Share70.91 USD
Dividends
Fwd Div Rate2.67 USD
Trail. Div Rate2.67 USD
Div. Yield4.26%
5Y Avg Yield5.48%
Payout Ratio11.50%
Ex-Div DateMar 23, 2026
Pay DateMar 25, 2025
Splits
Last Split5:1
Split DateMar 29, 2016
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)86.62 USD
Upside (mean)+38.8%
Target Range86.62 USD – 86.62 USD
# Analysts1
Ownership
Shares Out.55.15M
Float—
Insiders0.08%
Institutions20.71%
Technical
SMA 5060.73 (+2.8%)
SMA 20057.52 (+8.5%)
Beta0.68
S&P 52W Chg12.00%
Avg Vol (30d)79.22K
Avg Vol (10d)70.97K
Technical Indicators
RSI (14)53.2
MACD0.7500
MACD Signal0.7199
MACD Hist.+0.0301
BB Upper65.99 USD
BB Middle61.82 USD
BB Lower57.66 USD
BB Width13.48%
ATR (14)1.521 USD
Vol Ratio (20d)1.96x

About BB Biotech AG Ord (SWX: BION)

›

BB Biotech AG Ord (SWX: BION) is listed on the SIX Swiss Exchange, where its shares trade in CHF. It belongs to the Capital Markets industry, part of the Financial Services sector, and reports about 10 employees.

The shares were at 52.60 CHF on 19 November 2026, up 32.9% over 52 weeks. Its 52-week range is 41.05 CHF to 56.90 CHF: the price is 7.6% below the high and 28.1% above the low.

At a market capitalisation of 2.90B CHF, it trades at 2.7 times trailing earnings. The median trailing P/E of its 19 largest Capital Markets peers is 15.5, a discount of 83% for BION. It pays a dividend yielding 4.26% (it pays out 12% of its earnings), against a median of 1.81% among the dividend payers in that peer group.

BB Biotech AG Ord reports return on equity of 20.8%, an operating margin of 96.2% and revenue down 60.8% year over year.

It holds more cash than debt, a net cash position of 3.30B CHF. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. One analyst covers the stock, with an average rating of Buy; their mean price target of 73.00 CHF is 38.8% above the current price. The next earnings report is expected on 19 February 2027.